Idiopathic (Essential) Hypertension - Pipeline Review, H2 2016

  • ID: 3846530
  • Report
  • 62 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Actelion Ltd
  • Bayer AG
  • Eli Lilly and Company
  • Innopharmax Inc.
  • Quantum Genomics SA
  • MORE
Idiopathic (Essential) Hypertension - Pipeline Review, H2 2016

Summary

‘Idiopathic (Essential) Hypertension - Pipeline Review, H2 2016’, provides an overview of the Idiopathic (Essential) Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic (Essential) Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic (Essential) Hypertension and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Idiopathic (Essential) Hypertension
- The report reviews pipeline therapeutics for Idiopathic (Essential) Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Idiopathic (Essential) Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Idiopathic (Essential) Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Idiopathic (Essential) Hypertension

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Actelion Ltd
  • Bayer AG
  • Eli Lilly and Company
  • Innopharmax Inc.
  • Quantum Genomics SA
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Idiopathic (Essential) Hypertension Overview

Therapeutics Development

Pipeline Products for Idiopathic (Essential) Hypertension - Overview

Idiopathic (Essential) Hypertension - Therapeutics under Development by Companies

Idiopathic (Essential) Hypertension - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Idiopathic (Essential) Hypertension - Products under Development by Companies

Idiopathic (Essential) Hypertension - Companies Involved in Therapeutics Development

Actelion Ltd

Bayer AG

Chong Kun Dang Pharmaceutical Corp.

Daiichi Sankyo Company, Limited

Eli Lilly and Company

HanAll Biopharma Co., Ltd.

Innopharmax Inc.

Lee's Pharmaceutical Holdings Limited

PhaseBio Pharmaceuticals, Inc.

Quantum Genomics SA

Takeda Pharmaceutical Company Limited

Idiopathic (Essential) Hypertension - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(amlodipine besylate + candesartan cilexetil) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(atorvastatin calcium + losartan potassium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(candesartan cilexetil + nifedipine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

azilsartan medoxomil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carvedilol phosphate CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-3150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lisinopril - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-2623091 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PB-1046 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PB-1120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QGC-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rostafuroxin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Endothelin Receptor A and Endothelin Receptor B for Essential Hypertension - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Idiopathic (Essential) Hypertension - Dormant Projects

Idiopathic (Essential) Hypertension - Product Development Milestones

Featured News & Press Releases

Oct 06, 2015: Positive opinion from Monitoring Board to continue protocol as planned, for Phase IIa clinical trial under way for high blood pressure

Jun 12, 2013: Lee’s Pharma Enrolls First Patient in Phase IIb Clinical Trial of Rostafuroxin in Italy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Idiopathic (Essential) Hypertension, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Idiopathic (Essential) Hypertension - Pipeline by Actelion Ltd, H2 2016

Idiopathic (Essential) Hypertension - Pipeline by Bayer AG, H2 2016

Idiopathic (Essential) Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016

Idiopathic (Essential) Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H2 2016

Idiopathic (Essential) Hypertension - Pipeline by Eli Lilly and Company, H2 2016

Idiopathic (Essential) Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H2 2016

Idiopathic (Essential) Hypertension - Pipeline by Innopharmax Inc., H2 2016

Idiopathic (Essential) Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016

Idiopathic (Essential) Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016

Idiopathic (Essential) Hypertension - Pipeline by Quantum Genomics SA, H2 2016

Idiopathic (Essential) Hypertension - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Idiopathic (Essential) Hypertension - Dormant Projects, H2 2016

Idiopathic (Essential) Hypertension - Dormant Projects (Contd..1), H2 2016 58List of Figures

Number of Products under Development for Idiopathic (Essential) Hypertension, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Actelion Ltd
  • Bayer AG
  • Eli Lilly and Company
  • Innopharmax Inc.
  • Quantum Genomics SA
  • MORE
Idiopathic (Essential) Hypertension pipeline therapeutics constitutes close to 14 molecules. which approximately 14 molecules are developed by Companies. Our latest report Idiopathic (Essential) Hypertension – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Idiopathic (Essential) Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Idiopathic (Essential) Hypertension Essential hypertension (also called primary hypertension or idiopathic hypertension) is the form of hypertension that by definition has no identifiable cause. Essential hypertension increases with age, and individuals with relatively high blood pressure at younger ages are at increased risk for the subsequent development of hypertension. Hypertension increases the risk of cerebral, cardiac, and renal events. It can be caused by genetic predisposition, age and lifestyle habits such as inadequate physical activity, a high fat diet and high salt intake. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 4, 1, 1 and 1 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Idiopathic (Essential) Hypertension and features dormant and discontinued projects. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Actelion Ltd
Bayer AG
Chong Kun Dang Pharmaceutical Corp.
Daiichi Sankyo Company, Limited
Eli Lilly and Company
HanAll Biopharma Co., Ltd.
Innopharmax Inc.
Lee's Pharmaceutical Holdings Limited
PhaseBio Pharmaceuticals, Inc.
Quantum Genomics SA
Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll